FDA calendar · September 2022 · built from SEC filings

PDUFA dates September 2022: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in September 2022. The FDA calendar also recorded 32 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in September 2022

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

September 2022: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Sep 2022Month disclosedAMX0035AMLXFDA approvalALS in adultsApprovedSEC Form 10-K
Sep 2022Month disclosedAPHEXDA® (motixafortide)BLRXFDA approvalmultiple myelomaApprovedSEC Form 10-K
Sep 2022Month disclosedAPHEXDA® (motixafortide)BLRXNDA/BLA submissionmultiple myelomaCompletedSEC Form 10-K
Sep 2022Month disclosedAPONVIE® (aprepitant)HRTXFDA approval—ApprovedSEC 8-K Exhibit 99.1
Sep 2022Month disclosedAdcirca® (tadalafil)ONCOFDA approval—ApprovedSEC 8-K Exhibit 99.1
Sep 2022Month disclosedzabilugene almadenorepvec (VCN-01)TOVXFDA approval—ApprovedSEC Form 10-Q
Sep 2022Month disclosedHETLIOZ® (tasimelteon)VNDANDA/BLA submissionjet lag disorderCompletedSEC Form 10-Q
Sep 2022Month disclosedCopiktra (duvelisib)VSTMAdvisory committeerelapsed or refractory chronic lymphocytic leukemia/ small lymphocytic lymphomaNegativeSEC Form 10-K
September 2, 2022Imfinzi® (durvalumab)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
September 2, 2022Orkambi (ivacaftor; lumacaftor)VRTXLabel expansion—ApprovedopenFDA Drugs@FDA
September 9, 2022NurOwn (debamestrocel)BCLINDA/BLA submission—CompletedSEC Form 10-Q
September 9, 2022Sotyktu (deucravacitinib)BMYFDA approvalTo treat moderate-to-severe plaque psoriasisApprovedFDA Novel Drug Approvals
September 20, 2022cisplatin (DMS32212R)FENCFDA approval—Approvedsec_424b
September 20, 2022PEDMARKFENCFDA approval—ApprovedSEC 8-K Exhibit 99.1
September 21, 2022Retevmo (selpercatinib)LLYLabel expansion—ApprovedopenFDA Drugs@FDA
September 22, 2022Inlyta (axitinib)PFELabel expansion—ApprovedopenFDA Drugs@FDA
September 23, 2022Skyrizi (risankizumab-rzaa)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
September 27, 2022—CTORNDA/BLA accepted—CompletedSEC Form 10-Q
September 27, 2022—CTXRNDA/BLA accepted—CompletedSEC Form 10-Q
September 28, 2022Dupixent (dupilumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
September 29, 2022Relyvrio (sodium phenylbutyrate; taurursodiol)AMLXFDA approval—ApprovedFDA Novel Drug Approvals

September 2022: dated readouts

DateDrugCompanyEventIndicationStatusSource
Sep 2022Month disclosedABP-450AEONTopline readout—Met primary endpointSEC Form 10-Q
Sep 2022Month disclosedAmpligen® (rintatolimod)AIMTopline readout—NegativeSEC Form 10-Q
Sep 2022Month disclosed—ARQTTopline readout—PositiveSEC Form 10-K
Sep 2022Month disclosedZORYVE (roflumilast)ARQTTopline readout—PositiveSEC Form 10-Q
Sep 2022Month disclosed—ARQTTopline readout—PositiveSEC Form 10-K
Sep 2022Month disclosedverdiperstatBHVNTopline readoutparticipants with ALSNegativeSEC Form 10-K
September 27, 2022—NCELTopline readout—PositiveSEC Form 10-K

September 2022: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Sep 2022Month disclosedAUVELITY (dextromethorphan-bupropion)AXSMTrial startAD agitationCompletedSEC Form 10-K
Sep 2022Month disclosedMRT-2359GLUETrial start—CompletedSEC Form 10-K
Sep 2022Month disclosedatebimetinibIMRXTrial startwith advanced or metastatic solid tumorsCompletedSEC Form 10-Q
Sep 2022Month disclosedefzofitimod (ATYR1923)ATYRTrial start—Completedsec_424b

Questions

What PDUFA dates are in September 2022?

0 PDUFA dates fell in September 2022. The FDA calendar also recorded 32 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.